{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 50,
  "pageCount": 56,
  "prevPage": 49,
  "nextPage": 51,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "The chart displays individual patient responses categorized by dose level, with a list of specific notable responses on the right.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/50",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-50",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.62,
        "x": 0.03,
        "y": 0.165
      },
      "kind": "chart",
      "text": "Waterfall Plot of Tumor Response by Patient for Once Weekly Schedule Efficacy-Evaluable Analysis Set",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5b06e7a8-d858-4622-807e-ce4132459275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.7,
        "y": 0.35
      },
      "kind": "list",
      "text": "Four responses seen in patients with: BRAF V600E thyroid CA (180mg); BRAF K601E NSCLC (120mg); HRAS salivary gland CA (250mg); BRAF rearranged melanoma (250mg)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dce9609-cef5-446c-aba7-2ab3ff713ebc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.03,
        "y": 0.87
      },
      "kind": "source-note",
      "text": "Source: ASN007-101 study; as of the November 6, 2020, data extraction. Note: Best percent change from baseline in tumor lesions is defined as the maximum reduction in post-baseline tumor lesion diameter compared to baseline tumor lesion diameter.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8baaa999-1a9f-43da-aa16-df02ee735816",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "ERAS-007 Phase 1: Responses observed in patients with RAS and RAF alterations in diverse tumor types with single agent QW schedule",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad61a764-685b-41e4-86fb-383076702775",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "79dbc590-2c3d-45ce-94fa-d182faf67f8f",
      "evidence": "The slide features a waterfall plot of tumor response by patient.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}